3-(ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyrazine as an ion channel modulator
The present invention is directed to, in part, fused heteroaryl compounds, such as the compound: and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including neurological disorders (e.g., Dravet syndrome, epilepsy), pain, and neuromuscular disorders are also provided herein.
1. The compound:
or a pharmaceutically acceptable salt thereof.
2. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the compound:
or a pharmaceutically acceptable salt thereof.
3. The compound:
4. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the compound:
5. A crystalline form of the compound:
wherein the crystalline form is characterized by an X-ray powder diffraction pattern comprising X-ray power diffraction peaks at the following diffraction angles (° 2θ): 9.3°±0.2°, 18.8°±0.2°, and 21.4°±0.2° (2θ).
6. The crystalline form of claim 5 , wherein the crystalline form is further characterized by an X-ray powder diffraction pattern comprising additional X-ray powder diffraction peaks at the following diffraction angles (° 2θ): 16.1°±0.2°, 21.1°±0.2°, and 21.6°±0.2° (2θ).
7. The crystalline form of claim 5 , wherein the crystalline form is further characterized by an X-ray powder diffraction pattern comprising additional X-ray powder diffraction peaks at the following diffraction angles (° 2θ): 16.1°±0.2°, 21.1°±0.2°, 21.6°±0.2°, 22.6°±0.2°, 23.9°±0.2°, 26.0°±0.2°, and 26.4°±0.2° (2θ).
8. The crystalline form of claim 5 , wherein the crystalline form is characterized by an X-ray powder diffraction pattern as shown in FIG. 1A .
9. The crystalline form of claim 5 , wherein the X-ray powder diffraction pattern is obtained using Cu Kα radiation.
10. The crystalline form of claim 5 , wherein the crystalline form has a melting point onset as determined by differential scanning calorimetry at 122° C.
11. The crystalline form of claim 5 , wherein the crystalline form has a differential scanning calorimetry curve as shown in FIG. 1B .
12. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the crystalline form of claim 5 .
13. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the crystalline form of claim 6 .
14. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the crystalline form of claim 7 .
15. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the crystalline form of claim 8 .
16. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the crystalline form of claim 9 .
17. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the crystalline form of claim 10 .
18. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the crystalline form of claim 11 .